Tyra Biosciences Deal History & Licensing Activity
Tyra Biosciences is a biotech headquartered in Belgium. Over the past three years, Tyra Biosciences has been involved in 8 licensing and acquisition transactions, with a primary focus on CAR-T (2 deals).
Deals (12mo)
0
Active Trials
0
Top Modality
CAR-T
Focus Area
Oncology
Tyra Biosciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Tyra Biosciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| CLDN18.2 | Merck | CAR-T | Phase 2 | co development | Jan 2026 |
| PARP-mab | Pfizer | Peptides | Phase 1 | co development | Jan 2026 |
Tyra Biosciences Pipeline Focus
Therapeutic areas and modalities where Tyra Biosciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Tyra Biosciences Strategic Signals
Key indicators of Tyra Biosciences's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Tyra Biosciences's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Tyra Biosciences Licensing & Deal Activity
Tyra Biosciences is a biotech company based in Belgium that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Tyra Biosciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Tyra Biosciences include Oncology (10 deals and trials). In terms of modality, Tyra Biosciences has shown particular interest in car-t, peptides, cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Tyra Biosciences and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Tyra Biosciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.